CARBIDOPA AND LEVODOPA 25 mg/1, 100 mg/1 TABLET, ORALLY DISINTEGRATING
FDA Drug Information
Indications & Usage
INDICATIONS AND USAGE Carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson’s disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa orally disintegrating tablets. This is most likely due…
Important Warnings
WARNINGS When carbidopa and levodopa orally disintegrating tablet is to be given to patients who are being treated with levodopa, levodopa must be discontinued at least twelve hours before therapy with carbidopa and levodopa orally disintegrating tablet is started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiatin…
Source: FDA. For professional use only. Not a substitute for prescribing information.
Other CARBIDOPA AND LEVODOPA NDC Codes
Wholesale and compliance resources
Order NDC 47335-0187-88 at Wholesale
Create a free Premier Pharma account to unlock live wholesale pricing and place orders with same-day fulfillment and full DSCSA T2 documentation (TI + TS).